 |
Raptor Pharmaceutical Reports First Quarter Calendar Year 2013 Financial Results
May 8, 2013
|
30.3 KB |
|
| |
NOVATO, Calif., May 8, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Raptor or the Company) (Nasdaq:RPTP) today reported financial results for its first quarter ended March 31, 2013.
Financial Results for the First Quarter 2013 and Other Recent Highlights
Net loss for the first quarter ended March 31, 2013 was $15.9 mi...
|
|
Raptor Pharmaceutical Licenses Intellectual Property for Rett Syndrome From French Research Institutes
May 7, 2013
|
21.3 KB |
|
| |
Raptor Expands its Cysteamine Rights for the Treatment of Neurologic Disorders
License Grants Raptor Exclusive Worldwide Rights to the Use of Cysteamine and Related Compounds in the Treatment of MECP2-Associated Conditions
NOVATO, Calif., May 7, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) announced that it has...
|
|
Multimedia Now Available: Raptor Pharmaceutical's PROCYSBI™ Receives FDA Approval for the Treatment of Nephropathic Cystinosis
May 1, 2013
|
19.2 KB |
|
| |
NOVATO, Calif., May 1, 2013 /PRNewswire/ -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a...
|
|
Raptor Pharmaceutical's PROCYSBI™ Receives FDA Approval for the Treatment of Nephropathic Cystinosis
Apr 30, 2013
|
18.0 KB |
|
| |
NOVATO, Calif., April 30, 2013 /PRNewswire/ -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. I...
|
|
Raptor Pharmaceutical Corp. Reports Financial Results for the Transition Period From September 1, 2012 to December 31, 2012
Mar 14, 2013
|
28.6 KB |
|
| |
NOVATO, Calif., March 14, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today reported financial results for its four month transition period from September 1, 2012 to December 31, 2012.
Financial Results and Other Recent Highlights
Net loss for the four month transition period...
|
|
Raptor Pharmaceutical Corp. to Present at the Cowen and Company 33rd Annual Health Care Conference
Feb 26, 2013
|
15.5 KB |
|
| |
NOVATO, Calif., Feb. 26, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), today announced that Julie Anne Smith, executive vice president, strategy and chief operating officer of Raptor, will present an overview of the company at the Cowen and Company 33rd Annual Health Care Conference in Boston at the Marriott Copley Place. Rapt...
|
|
Raptor Pharmaceutical Corp. to Present at Upcoming Investor Conferences
Feb 5, 2013
|
19.1 KB |
|
| |
NOVATO, Calif., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), today announced that the company's management will present at two upcoming investor conferences in February. Julie Anne Smith, executive vice president, strategy and chief operating officer of Raptor, will present an overview of the company at the 15th Annua...
|
|
Raptor Pharmaceutical Corp. Reports First Quarter Fiscal Year 2013 Financial Results
Jan 9, 2013
|
35.3 KB |
|
| |
NOVATO, Calif., Jan. 9, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today reported financial results for its first fiscal quarter ended November 30, 2012.
Financial Results and Other Recent Highlights
Net loss for the fiscal first quarter ended November 30, 2012 was approxima...
|
|
Raptor Pharmaceutical Corp. Provides Update on PROCYSBI™ NDA Review
Dec 21, 2012
|
26.0 KB |
|
| |
NOVATO, Calif., Dec. 21, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that the U.S. Food and Drug Administration ("FDA") will require additional time to complete its review of the New Drug Application ("NDA") for RP103 (PROCYSBI™), for the potential treatment of nephropathic c...
|
|
Raptor Pharmaceutical Corp. Signs $50 Million Loan Agreement With HealthCare Royalty Partners
Dec 20, 2012
|
27.7 KB |
|
| |
NOVATO, Calif., Dec. 20, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that it has signed a $50 million loan agreement with HealthCare Royalty Partners ("HC Royalty") to help fund the commercialization of PROCYSBI™, the branded name of RP103 for the potential treatment of nephr...
|
|
Raptor Pharmaceutical Corp. Reports Fourth Quarter and Fiscal Year 2012 Financial Results
Nov 14, 2012
|
26.6 KB |
|
| |
NOVATO, Calif., Nov. 14, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today reported financial results for its fourth quarter and fiscal year ended August 31, 2012.
Cash Position
Raptor's cash, cash equivalents and short-term investments ("Cash") as of August 31, 2012 were approxima...
|
|
Raptor Pharmaceutical Corp. to Present at the Lazard Capital Markets 9th Annual Healthcare Conference 2012
Nov 9, 2012
|
22.4 KB |
|
| |
NOVATO, Calif., Nov. 9, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that Julie Anne Smith, Executive Vice President, Strategy and Chief Operating Officer of Raptor, will present an overview of the Company at the Lazard Capital Markets 9th Annual Healthcare Conference in New York, N...
|
|
Raptor Pharmaceutical Corp. Announces Positive Data on RP103 Extension Study Presented at Kidney Week 2012
Nov 5, 2012
|
28.7 KB |
|
| |
NOVATO, Calif., Nov. 5, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), announced that Craig B. Langman, M.D., Head of Kidney Diseases, and the Isaac A. Abt, M.D., Professor of Kidney Diseases and Tenured Professor of Pediatrics, Northwestern University Feinberg School of Medicine, presented on Saturd...
|
|
Raptor Pharmaceutical Corp. Reports Fiscal Year 2012 Financial Highlights and Program Updates
Nov 1, 2012
|
28.2 KB |
|
| |
NOVATO, Calif., Nov. 1, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the Company") (Nasdaq:RPTP) today announced its fiscal year 2012 ended August 31, 2012 financial highlights, and updates on its clinical programs including the ongoing extension study of PROCYSBI™ (cysteamine bitartrate) delayed-release capsules for the ...
|
|
Raptor Pharmaceutical Corp. Announces Presentation of PROCYSBI(TM) (RP103) Extension Study Data at the ASN Annual Meeting
Oct 17, 2012
|
27.5 KB |
|
| |
NOVATO, Calif., Oct. 17, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), announced that Craig B. Langman, M.D., Head of Kidney Diseases, and the Isaac A. Abt, M.D., Professor of Kidney Diseases and Tenured Professor of Pediatrics, Northwestern University Feinberg School of Medicine, will present a Lat...
|
|
Raptor Pharmaceutical Obtains Tissue Fibrotic Disease Intellectual Property Related to Cysteamine
Oct 10, 2012
|
29.9 KB |
|
| |
NOVATO, Calif., Oct. 10, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that the Company has acquired exclusive world-wide rights to intellectual property related to cysteamine and related compounds in the potential treatment of tissue fibrosis from the Seattle Children's Research Ins...
|
|
Raptor Pharmaceutical Corp. Expands Senior Management
Sep 10, 2012
|
26.7 KB |
|
| |
NOVATO, Calif., Sept. 10, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced the appointment of Georgia Erbez, as Chief Financial Officer of Raptor, and Julie Anne Smith, as Executive Vice President, Strategy, and Chief Operating Officer.
Ms. Erbez will be responsible for directin...
|
|
Raptor Pharmaceutical Corp. to Present at the Stifel Nicolaus Healthcare Conference 2012
Aug 30, 2012
|
22.7 KB |
|
| |
NOVATO, Calif., Aug. 30, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that Christopher M. Starr, Ph.D., Chief Executive Officer of Raptor, will present an overview of the Company at the Stifel Nicolaus Healthcare Conference in Boston, MA at the Four Seasons Hotel. Raptor's presentat...
|
|
Raptor Pharmaceutical Corp. to Present at Two Upcoming Investor Conferences
Aug 7, 2012
|
23.5 KB |
|
| |
NOVATO, Calif., Aug. 7, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that Ted Daley, President of Raptor, will present an overview of the Company at two investor conferences in August.
The conference presentation schedule is as follows:
Canaccord...
|
|
Raptor Pharmaceutical Announces Issuance of Key European Patent Protecting the Cysteamine Portfolio
Jul 30, 2012
|
27.7 KB |
|
| |
NOVATO, Calif., July 30, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that the European Patent Office has issued a key patent covering enteric-coated oral formulations of cysteamine bitartrate, including the Company's proprietary microbead formulation, RP103. Decision to Grant the p...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter